Lectus Therapeutics Limited (LTL) is a
pharmaceutical company based in the United Kingdom. LTL
specialized in the discovery and development of novel drug
candidates within the therapeutic areas of neuropathic pain and
related indications.
LTL divested its key pharmaceutical assets
to UCB in Q4 of 2011Click here for details
and will continue trading for a number of years in order to receive
and distribute revenues to shareholders.
LTL's pharmaceutical assets were identified
using its proprietary technology LEPTICS®:
Leveraged
Enabling
Proteomics
Technology for
Ion
Channel
Screening. Licensing
opportunities around a variety of ion channel targets still
exist. Interested parties should contact the company by e mail
at
info@lectusth.com.
Or by
mail to:
Lectus Therapeutics Limited (Registered Office)
Portland Street
Manchester
M1 3BE, UK
